Thursday, August 8, 2019 NIH-Funded Study Will Test Seasonal Flu Vaccines With Two Experimental Adjuvants In addition to developing new, more effective influenza vaccines, NIAID supports efforts to improve the seasonal flu vaccines already available. In a new Phase 1 trial taking place at NIAID-funded sites across the United States, researchers will test the safety and immune response of two established seasonal influenza vaccines, Fluzone and Flublok (both manufactured by Sanofi Pasteur, the vaccines global business unit of Sanofi), when given on their own, or with one of two novel adjuvants. These adjuvants, AF03 (manufactured by Sanofi Pasteur) and Advax-CpG55.2™ (manufactured by Vaxine Pty Ltd) are designed to boost recipients’ immune responses to the vaccines.